The GSK vaccine was practically 83 % efficient in decrease respiratory tract sickness in a examine of about 25,000 sufferers — half on the vaccine and half on a placebo, in line with information the corporate supplied to the F.D.A. No R.S.V. deaths had been reported among the many sufferers within the GSK or Pfizer research.
A number of panel members expressed issues about unwanted side effects reported with every vaccine. After seven days, one affected person who acquired the Pfizer vaccine developed Guillain-Barré syndrome, a situation the place the immune system assaults the nervous system (however not the backbone or mind). The case was thought of life-threatening, F.D.A. information present, although a “doubtlessly confounding issue” was that the affected person had suffered a coronary heart assault the day earlier than the situation developed.
One other Pfizer vaccine recipient developed Miller Fisher syndrome, which is taken into account to be a sort of Guillain-Barré, eight days after getting the shot. That affected person, from Japan, reported double imaginative and prescient and a tingling or burning feeling in her palms and the soles of her ft. Her signs had been principally resolved inside 41 days, the F.D.A. information mentioned.
The 2 instances within the Pfizer examine put the speed of the situation at about one in 9,000, although it’s usually about one in 100,000, in line with Dr. Hana El Sahly, chairwoman of the vaccine advisory committee and a professor of virology at Baylor School of Drugs. “So that is main,” Dr. El Sahly mentioned.
Dr. Marie Griffin, a well being coverage professor at Vanderbilt College, mentioned the Pfizer vaccine was tough to guage given the low incidence of extreme infections amongst these within the trial.
“I feel the profit for comparatively wholesome, older individuals — you need to think about that — is just not that nice,” Dr. Griffin mentioned. “In comparison with a attainable excessive danger of a really extreme consequence.”
One recipient of the GSK vaccine, who was 78 and from Japan, additionally developed Guillain-Barré 9 days after getting the vaccine; she went on to spend six months in a rehabilitation hospital. The corporate and the F.D.A. thought of the case to be associated to the vaccine.
